Table 3.
Probe sets indicating decreased expression of genes in orbital adipose tissues from subjects with GPA.
| Probe Set | Gene Title | Set 1 | Set2 | ||
|---|---|---|---|---|---|
| Fold Difference |
FDR P- value |
Fold Difference |
FDR P- value |
||
| 205913_at | perilipin 1 | −143.00 | 1.25E-04 | −121.91 | 1.11E-05 |
| 209612_s_at | alcohol dehydrogenase 1B (class I), β polypeptide |
−105.20 | 5.19E-05 | −110.27 | 8.66E-06 |
| 207175_at | adiponectin, C1Q and collagen domain containing |
−91.04 | 2.35E-04 | −67.65 | 2.89E-05 |
| 205478_at | protein phosphatase 1, regulatory (inhibitor) subunit 1A |
−54.07 | 5.49E-05 | −69.20 | 3.00E-06 |
| 1565162_s_at | microsomal glutathione S-transferase 1 | −37.42 | 1.95E-04 | −69.65 | 8.09E-07 |
| 219398_at | cell death-inducing DFFA-like effector c | −47.89 | 3.18E-05 | −52.73 | 1.65E-05 |
| 226304_at | heat shock protein, α-crystallin-related, B6 |
−13.64 | 1.57E-03 | −80.10 | 9.01E-06 |
| 203980_at | fatty acid binding protein 4, adipocyte | −43.92 | 4.28E-04 | −44.16 | 9.18E-05 |
| 225420_at | glycerol-3-phosphate acyltransferase, mitochondrial |
−48.61 | 8.73E-05 | −38.56 | 9.04E-05 |
| 201540_at | four and a half LIM domains 1 | −25.32 | 6.97E-04 | −55.33 | 2.54E-05 |
| 209699_x_at | aldo-keto reductase family 1, member C2 | −33.58 | 5.20E-06 | −42.33 | 1.65E-05 |
| 211356_x_at | leptin receptor | −24.20 | 4.22E-04 | −37.59 | 4.87E-06 |
| 209555_s_at | CD36 molecule (thrombospondin receptor) |
−34.54 | 1.22E-03 | −27.21 | 2.79E-04 |
| 202036_s_at | secreted frizzled-related protein 1 | −31.23 | 1.21E-05 | −27.05 | 2.42E-07 |
| 204151_x_at | aldo-keto reductase family 1, member C1 | −17.12 | 3.04E-05 | −40.77 | 1.76E-05 |
| 209283_at | crystallin, αB | −10.13 | 2.11E-03 | −46.48 | 4.25E-05 |
| 212097_at | caveolin 1, caveolae protein, 22kDa | −14.11 | 7.32E-04 | −39.56 | 6.29E-05 |
| 204894_s_at | amine oxidase, copper containing 3 | −30.59 | 2.46E-04 | −22.59 | 2.55E-05 |
| 219140_s_at | retinol binding protein 4, plasma | −23.29 | 6.10E-06 | −27.16 | 1.87E-05 |
| 222124_at | hypoxia inducible factor 3, α subunit | −18.41 | 5.96E-03 | −31.88 | 6.02E-05 |
| 221796_at | neurotrophic tyrosine kinase, receptor, type 2 |
−18.69 | 2.24E-04 | −30.75 | 1.31E-05 |
| 229476_s_at | thyroid hormone responsive | −20.58 | 2.24E-04 | −28.73 | 4.43E-05 |
| 203324_s_at | caveolin 2 | −12.07 | 5.31E-03 | −35.52 | 2.89E-06 |
| 203407_at | periplakin | −17.08 | 8.92E-06 | −27.81 | 1.11E-06 |
| 222513_s_at | sorbin and SH3 domain containing 1 | −10.64 | 1.67E-03 | −34.00 | 8.86E-05 |
| 205498_at | growth hormone receptor | −19.66 | 1.40E-04 | −24.45 | 7.97E-06 |
| 202016_at | mesoderm specific transcript | −19.57 | 2.23E-04 | −21.60 | 9.30E-06 |
| 204719_at | ATP-binding cassette, sub-family A (ABC1), member 8 |
−21.77 | 7.39E-04 | −18.77 | 8.67E-06 |
| 1555740_a_at | melanocortin 2 receptor accessory protein |
−19.05 | 3.34E-04 | −20.58 | 4.22E-05 |
| 212230_at | phosphatidic acid phosphatase type 2B | −13.57 | 1.30E-03 | −26.03 | 7.54E-06 |
| 210963_s_at | glycogenin 2 | −20.66 | 4.64E-04 | −18.21 | 6.38E-05 |
| 213524_s_at | G0/G1switch 2 | −13.65 | 4.73E-03 | −24.89 | 1.41E-04 |
| 222835_at | thrombospondin, type I, domain containing 4 |
−13.50 | 2.27E-03 | −24.22 | 6.56E-05 |
| 201432_at | catalase | −10.70 | 1.20E-03 | −25.30 | 2.14E-05 |
| 209763_at | chordin-like 1 | −16.42 | 9.03E-04 | −19.39 | 6.03E-06 |
| 225207_at | pyruvate dehydrogenase kinase, isozyme 4 |
−13.50 | 1.04E-02 | −21.80 | 8.69E-05 |
| 221748_s_at | tensin 1 | −9.92 | 2.77E-04 | −25.36 | 9.14E-04 |
| 225975_at | protocadherin 18 | −16.49 | 1.15E-04 | −18.31 | 3.06E-06 |
| 212741_at | monoamine oxidase A | −16.69 | 1.37E-04 | −18.01 | 2.38E-06 |
| 243585_at | ATPase type 13A5 | −14.16 | 3.23E-04 | −19.16 | 6.14E-06 |
| 219789_at | natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C) |
−15.40 | 4.13E-04 | −17.67 | 7.73E-07 |
| 203851_at | insulin-like growth factor binding protein 6 |
−9.38 | 1.10E-03 | −20.16 | 3.77E-06 |
| 222484_s_at | chemokine (C-X-C motif) ligand 14 | −5.60 | 4.36E-02 | −23.53 | 1.30E-03 |
| 228224_at | proline/arginine-rich end leucine-rich repeat protein |
−6.57 | 1.93E-02 | −21.02 | 7.12E-06 |
| 211959_at | insulin-like growth factor binding protein 5 |
−9.01 | 9.98E-03 | −18.21 | 1.56E-04 |
| 206243_at | TIMP metallopeptidase inhibitor 4 | −9.02 | 4.52E-03 | −18.13 | 5.55E-05 |
| 227646_at | early B-cell factor 1 | −9.45 | 2.29E-03 | −17.15 | 1.28E-05 |
| 212071_s_at | spectrin, β, non-erythrocytic 1 | −6.58 | 2.51E-03 | −19.02 | 4.42E-04 |
| 203571_s_at | adipogenesis regulatory factor | −7.67 | 2.98E-04 | −16.93 | 3.89E-05 |
| 201525_at | apolipoprotein D | −4.64 | 7.20E-03 | −18.85 | 1.02E-03 |
Shown here are 50 probe sets with the largest negative fold differences compared to uninflamed control tissues and with adequate annotation. For genes interrogated by multiple probe sets, only the one with the largest negative fold difference is listed here. The entire list of probe sets with significantly lower signals is in Supplemental Table 2.